We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Elan, Andrx Antitrust Battle Over Naproxen Deal Heads Back To District Court

Law360 (September 6, 2005, 12:00 AM EDT) -- A federal appeals court has reinstated part of an antitrust challenge to a deal between Irish drug maker Elan and Skyepharma over a generic version of the non-steroidal anti-inflammatory drug Naprelan (naproxen sodium).

The U.S. Court of Appeals for the 11th Circuit agreed with a Florida district court that the Noerr-Pennington doctrine immunized Elan from an antitrust suit based on generic maker Andrx’s allegations that Elan filed a sham lawsuit to protect its monopoly on the market for a controlled release naproxen medication.

However, the court...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.